Literature DB >> 31562226

Comparison of 3 Interpretation Criteria for 68Ga-PSMA11 PET Based on Inter- and Intrareader Agreement.

Akira Toriihara1, Tomomi Nobashi1, Lucia Baratto1, Heying Duan1, Farshad Moradi1, Sonya Park1, Negin Hatami1, Carina Mari Aparici1, Guido Davidzon1, Andrei Iagaru2.   

Abstract

PET using radiolabeled prostate-specific membrane antigen (PSMA) is now being more widely adopted as a valuable tool to evaluate patients with prostate cancer (PC). Recently, 3 different criteria for interpretation of PSMA PET were published: the European Association of Nuclear Medicine (EANM) criteria, the Prostate Cancer Molecular Imaging Standardized Evaluation criteria, and the PSMA Reporting and Data System. We compared these 3 criteria in terms of interreader, intrareader, and intercriteria agreement.
Methods: Data from 104 patients prospectively enrolled in research protocols at our institution were retrospectively reviewed. The cohort consisted of 2 groups: 47 patients (mean age, 64.2 y old) who underwent Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)] (68Ga-PSMA11) PET/MRI for initial staging of biopsy-proven intermediate- or high-risk PC, and 57 patients (mean age, 70.5 y old) who underwent 68Ga-PSMA11 PET/CT because of biochemically recurrent PC. Three nuclear medicine physicians independently evaluated all 68Ga-PSMA11 PET/MRI and PET/CT studies according to the 3 interpretation criteria. Two of them reevaluated all studies 6 mo later in the same manner and masked to the initial reading. The Gwet agreement coefficient was calculated to evaluate interreader, intrareader, and intercriteria agreement based on the following sites: local lesion (primary tumor or prostate bed after radical prostatectomy), lymph node metastases, and other metastases.
Results: In the PET/MRI group, interreader, intrareader, and intercriteria agreement ranged from substantial to almost perfect for any site according to all 3 criteria. In the PET/CT group, interreader agreement ranged from substantial to almost perfect except for judgment of distant metastases based on the PSMA Reporting and Data System (Gwet agreement coefficient, 0.57; moderate agreement), in which the most frequent cause of disagreement was lung nodules. Intrareader agreement ranged from substantial to almost perfect for any site according to all 3 criteria. Intercriteria agreement for each site was also substantial to almost perfect.
Conclusion: Although the 3 published criteria have good interreader and intrareader reproducibility in evaluating 68Ga-PSMA11 PET, there are some factors causing interreader disagreement. Further work is needed to address this issue.
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

Entities:  

Keywords:  68Ga-PSMA11; PET/CT; PET/MRI; interpretation criteria; interreader agreement

Mesh:

Substances:

Year:  2019        PMID: 31562226     DOI: 10.2967/jnumed.119.232504

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  15 in total

1.  High Interobserver Agreement for the Standardized Reporting System SSTR-RADS 1.0 on Somatostatin Receptor PET/CT.

Authors:  Rudolf A Werner; Thorsten Derlin; Steven P Rowe; Lena Bundschuh; Gabriel T Sheikh; Martin G Pomper; Sebastian Schulz; Takahiro Higuchi; Andreas K Buck; Frank M Bengel; Ralph A Bundschuh; Constantin Lapa
Journal:  J Nucl Med       Date:  2020-08-28       Impact factor: 10.057

Review 2.  Prebiopsy 68Ga-PSMA PET imaging: can we improve the current diagnostic pathway for prostate cancer?

Authors:  Simone Albisinni; Julien Sarkis; Romain Diamand; Cosimo De Nunzio
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-09-09       Impact factor: 5.455

3.  68Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement.

Authors:  Daniela A Ferraro; Andreas M Hötker; Olivio F Donati; Irene A Burger; Anton S Becker; Iliana Mebert; Riccardo Laudicella; Anka Baltensperger; Niels J Rupp; Jan H Rueschoff; Julian Müller; Ashkan Mortezavi; Marcelo T Sapienza; Daniel Eberli
Journal:  Eur J Hybrid Imaging       Date:  2022-07-18

Review 4.  Influences on PET Quantification and Interpretation.

Authors:  Julian M M Rogasch; Frank Hofheinz; Lutz van Heek; Conrad-Amadeus Voltin; Ronald Boellaard; Carsten Kobe
Journal:  Diagnostics (Basel)       Date:  2022-02-10

Review 5.  Seek and Find: Current Prospective Evidence for Prostate-specific Membrane Antigen Imaging to Detect Recurrent Prostate Cancer.

Authors:  Niamh M Keegan; Lisa Bodei; Michael J Morris
Journal:  Eur Urol Focus       Date:  2021-03-18

Review 6.  The Emerging Role of Next-Generation Imaging in Prostate Cancer.

Authors:  Vishnu Murthy; Rahul Aggarwal; Phillip J Koo
Journal:  Curr Oncol Rep       Date:  2022-01-20       Impact factor: 5.075

7.  Survey by the French Medicine Agency (ANSM) of the imaging protocol, detection rate, and safety of 68Ga-PSMA-11 PET/CT in the biochemical recurrence of prostate cancer in case of negative or equivocal 18F-fluorocholine PET/CT: 1084 examinations.

Authors:  Yanna-Marina Chevalme; Lotfi Boudali; Mathieu Gauthé; Caroline Rousseau; Andrea Skanjeti; Charles Merlin; Philippe Robin; Anne-Laure Giraudet; Marc Janier; Jean-Noël Talbot
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-01-08       Impact factor: 9.236

8.  PSMA PET for primary lymph node staging of intermediate and high-risk prostate cancer: an expedited systematic review.

Authors:  Lars J Petersen; Helle D Zacho
Journal:  Cancer Imaging       Date:  2020-01-23       Impact factor: 3.909

9.  The influence of digital PET/CT on diagnostic certainty and interrater reliability in [68Ga]Ga-PSMA-11 PET/CT for recurrent prostate cancer.

Authors:  Ian Alberts; Jan-Niklas Hünermund; Christos Sachpekidis; Clemens Mingels; Viktor Fech; Karl Peter Bohn; Axel Rominger; Ali Afshar-Oromieh
Journal:  Eur Radiol       Date:  2021-04-15       Impact factor: 5.315

10.  68Ga-PSMA-11 PET imaging in patients with ongoing androgen deprivation therapy for advanced prostate cancer.

Authors:  Saskia Fassbind; Daniela A Ferraro; Jean-Jacques Stelmes; Christian D Fankhauser; Matthias Guckenberger; Philipp A Kaufmann; Daniel Eberli; Irene A Burger; Benedikt Kranzbühler
Journal:  Ann Nucl Med       Date:  2021-06-29       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.